<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="6694"><DrugName>DHAC</DrugName><DrugSynonyms><Name><Value>DHAC</Value></Name><Name><Value>NSC-264880</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>62488-57-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20518">National Institutes of Health</CompanyOriginator><CompaniesSecondary><Company id="18203">MGI Pharma Inc</Company><Company id="20518">National Institutes of Health</Company><Company id="23744">ILEX Oncology Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6694" type="Drug"><TargetEntity id="90632" type="siDrug">DHAC</TargetEntity></SourceEntity><SourceEntity id="18203" type="Company"><TargetEntity id="4295907032" type="organizationId">MGI Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="20518" type="Company"><TargetEntity id="5001347606" type="organizationId">National Institutes of Health</TargetEntity></SourceEntity><SourceEntity id="23744" type="Company"><TargetEntity id="4295906762" type="organizationId">Ilex Oncology Inc</TargetEntity></SourceEntity><SourceEntity id="1240" type="ciIndication"><TargetEntity id="C45" type="ICD10"></TargetEntity><TargetEntity id="163" type="ICD9"></TargetEntity><TargetEntity id="10027406" type="MEDDRA"></TargetEntity><TargetEntity id="D008654" type="MeSH"></TargetEntity><TargetEntity id="50251" type="ORPHANET"></TargetEntity><TargetEntity id="-666440137" type="omicsDisease"></TargetEntity><TargetEntity id="2015" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"></TargetEntity><TargetEntity id="10028533" type="MEDDRA"></TargetEntity><TargetEntity id="D011289" type="MeSH"></TargetEntity><TargetEntity id="-376765165" type="omicsDisease"></TargetEntity><TargetEntity id="711" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1240">Mesothelioma</Indication><Indication id="1272">Myelodysplastic syndrome</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-07-03T11:07:12.000Z</LastModificationDate><ChangeDateLast>2018-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23744" linkType="Company"&gt;ILEX Oncology&lt;/ulink&gt; was developing DHAC (dihydro-5-azacystidine), under license from the &lt;ulink linkID="20518" linkType="Company"&gt;National Institutes of Health&lt;/ulink&gt;,  as a therapy for myelodysplastic syndrome. The product was discontinued due to the success of a competing product which is further along in development [&lt;ulink linkID="272155" linkType="reference"&gt;272155&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In a phase II trial in 36 patients with mesothelioma treated with a combination of DHAC and cisplatin every 21 days, the addition of cisplatin was found to result in increased myelosuppression but no increase was observed in response rate or median survival compared with title compound alone [&lt;ulink linkID="181490" linkType="reference"&gt;181490&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 1996, MGI Pharma acquired the world wide rights to DHAC but these were subsequently returned [&lt;ulink linkID="272155" linkType="reference"&gt;272155&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18203">MGI Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-11-03T00:00:00.000Z</StatusDate><Source id="268198" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23744">ILEX Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-12-05T00:00:00.000Z</StatusDate><Source id="228392" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18203">MGI Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-12-12T00:00:00.000Z</StatusDate><Source id="228392" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23744">ILEX Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1240">Mesothelioma</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23744">ILEX Oncology Inc</OwnerCompany><Country id="US">US</Country><Indication id="1240">Mesothelioma</Indication><AwardedIndication>Treatment of malignant mesothelioma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-05-11T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15872">Eisai Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C1NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N</Smiles></StructureSmiles><Deals><Deal id="116604" title="MGI to develop Ilex's DHAC worldwide"></Deal><Deal id="116605" title="ILEX to develop NIH's DHAC"></Deal></Deals><PatentFamilies><PatentFamily id="1165282" number="WO-09803183" title="Use of 5,6-dihydro-5-azacytidine in the treatment of prostate cancer."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>